MedTrace Logo

Anti-Inflammatory Effect of Statins in the Human Endotoxin Model

NCT00309374 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2007-01-05

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of HMG-CoA reductase inhibitor pretreatment on inflammation and coagulation activation in human endotoxemia.

Conditions

  • Endotoxemia

Interventions

DRUG

LPS 2ng/kg intravenous bolus

DRUG

Simvastatin 80mg; administered daily p.o. over 5 days

DRUG

Rosuvastatin 40mg; administered daily p.o. over 5 days

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Michael Wolzt, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Completion
2006-07-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00309374 on ClinicalTrials.gov